Weekly Irinotecan in Patients with Metastatic Gastric Cancer Failing Cisplatin-based Chemotherapy

Chun, June Young; Kim, Hark Kyun; Lee, Jong Seok; Choi, Jin Yi; Lee, Hong Gi; Yoon, Sung Min; Choi, Il Ju; Ryu, Keun Won; Kim, Young Woo; Bae, Jae-Moon

doi:10.1093/jjco/hyh006

Cited by 70 publications

(40 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In these studies, PFS was reported to range between 2.2 and 4.5 months, whereas OS was reported to vary between 3. 5 and 8 months (Graziano et al, 2000;Giuliani et al, 2003;Chun et al, 2004;Cho et al, 2006;Kodera et al, 2007;Jeong et al, 2008;Sym et al, 2008;Baize et al, 2009;Seo et al, 2009;Kim et al, 2010). In our study, PFS was 3.26 months and OS was 8.76 months.…”

Section: Discussionsupporting

confidence: 61%

Second-Line Irinotecan after Cisplatin, Fluoropyrimidin and Docetaxel for Chemotherapy of Metastatic Gastric Cancer

Küçükzeybek¹,

Dirican²,

Erten³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Aim: Tumors of upper gastrointestinal tract are among the cancers that have a quite lethal course. Cytotoxic chemotherapy is the most efficient therapeutic modality for metastatic gastric cancer. In patients who do not respond to first-line treatment, the response rate to second-line therapies is generally low and the toxicity rates high. This study concerned the efficacy and the side effect profile of second-line therapy with irinotecan in the patients who were being followed-up with the diagnosis of metastatic gastric cancer in İzmir, Turkey.

show abstract

Section: Discussionsupporting

confidence: 61%

Second-Line Irinotecan after Cisplatin, Fluoropyrimidin and Docetaxel for Chemotherapy of Metastatic Gastric Cancer

Küçükzeybek¹,

Dirican²,

Erten³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Our study was designed to prove a 1-year survival of 30%, which is somewhat high considering the patients' general condition and proportion of prior exposure to chemotherapy. Nevertheless, this survival rate is a currently acceptable range expected from any new regimen aiming at second-or third-line treatment for gastric cancer (Assersohn et al, 2004;Chun et al, 2004;Wilson et al, 2005;Horinaka et al, 2006).…”

Section: S-1 Monotherapy In Poor Performance Status H-c Jeung Et Almentioning

confidence: 98%

A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status

et al. 2007

View full text Add to dashboard Cite

Systemic chemotherapy for gastric cancer is often associated with treatment-related toxicity, which is particularly severe in patients with a poor performance status. In this paper, we describe the first study to evaluate S-1 monotherapy as an option for advanced gastric cancer patients who are not candidates for combination chemotherapy due to poor clinical condition. Fifty-two patients with Eastern Cooperative Oncology Group (ECOG) performance scale 2 -3, whose general condition had made use of combination chemotherapy impossible, were enrolled. S-1 was administered to 30 patients as second-or third-line therapy. The initial dose of S-1 was 35 mg m À2 , administered b.i.d for 14 days every 3 weeks. With a median follow-up period of 33 weeks, the median progressionfree survival, and overall survival were 11 weeks (95% CI, 8 -14) and 33 weeks (95% CI, 19 -47), respectively. The overall 1-year survival rate was 29% by intent-to-treat analysis. The overall response rate was 12% (95% CI, 3 -21), and the percentage of stable disease was 35%, resulting in the disease control rate of 47% (95% CI, 32 -60). Significant drug-related toxicity included grade 3 diarrhoea (14%), anorexia (14%), fatigue (10%), neutropenia (10%), and leucopenia (6%). In conclusion, this study indicated the modest activity of S-1 in gastric cancer patients with poor performance status.

show abstract

“…A number of agents have previously demonstrated second-line activity in AGC in Phase II trials, with modest benefit; however, no single regimen has shown superior activity [59][60][61][62][63][64]. Several Phase II trials assessing the benefit of targeted second-line therapies have demonstrated ability to achieve disease stabilization (everolimus/RAD001 [65], ramucirumab/IMC-1121B [66], sunitinib [67], cetuximab [68] and lapatinib in HER2-positive disease [69]) and there are a number of ongoing randomized trials assessing the impact of such agents on survival outcomes.…”

Section: Second-line Treatment Of Agcmentioning

confidence: 99%

Management of advanced gastric cancer

Price¹,

Shapiro

Segelov

et al. 2012

Expert Review of Gastroenterology & Hepatology

View full text Add to dashboard Cite

Weekly Irinotecan in Patients with Metastatic Gastric Cancer Failing Cisplatin-based Chemotherapy

Abstract: This weekly schedule of irinotecan was modestly active against cisplatin-refractory gastric cancer and relatively well-tolerated with appropriate dose modification.

Cited by 70 publications

References 22 publications

Second-Line Irinotecan after Cisplatin, Fluoropyrimidin and Docetaxel for Chemotherapy of Metastatic Gastric Cancer

Second-Line Irinotecan after Cisplatin, Fluoropyrimidin and Docetaxel for Chemotherapy of Metastatic Gastric Cancer

A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status

Management of advanced gastric cancer

Contact Info

Product

Resources

About